Uncoupling of sympathetic nervous system and hypothalamic-pituitary-adrenal axis in cirrhosis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 23, Issue 12, 2008, Pages 1901-1908

  Wiest, Reiner ^a   Moleda, Lukas ^a   Zietz, Bettina ^a   Hellerbrand, Claus ^a   Schölmerich, Jürgen ^a   Straub, Rainer ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Cirrhosis; Cortisol; Infection; Neuropeptide Y; Sympathetic nervous system

Indexed keywords

CORTICOTROPIN; HYDROCORTISONE; NEUROPEPTIDE Y; TRANSCORTIN;

ADRENERGIC SYSTEM; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFECTION SENSITIVITY; LIVER CIRRHOSIS; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STRESS;

EID: 57049120433     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2008.05456.x     Document Type: Article

References (58)

1. Zietz B, Lock G, Plach B et al. Dysfunction of the hypothalamic- pituitary-glandular axes and relation to Child-Pugh classification in male patients with alcoholic and virus-related cirrhosis. Eur. J. Gastroenterol. Hepatol. 2003 15 : 495 501.
2. Henriksen JH, Ring-Larsen H, Christensen NJ. Aspects of sympathetic nervous system regulation in patients with cirrhosis: a 10-year experience. Clin. Physiol. 1991 11 : 293 306.
3. Henriksen JH, Ring-Larsen H, Kanstrup IL, Christensen NJ. Splanchnic and renal elimination and release of catecholamines in cirrhosis. Evidence of enhanced sympathetic nervous activity in patients with decompensated cirrhosis. Gut 1984 25 : 1034 43.
4. Nicholls KM, Shapiro MD, Van Putten VJ et al. Elevated plasma norepinephrine concentrations in decompensated cirrhosis. Association with increased secretion rates, normal clearance rates, and suppressibility by central blood volume expansion. Circ. Res. 1985 56 : 457 61.
5. Floras JS, Legault L, Morali GA, Hara K, Blendis LM. Increased sympathetic outflow in cirrhosis and ascites: direct evidence from intraneural recordings. Ann. Intern. Med. 1991 114 : 373 80.
6. Pozzi M, Grassi G, Redaelli E et al. Patterns of regional sympathetic nerve traffic in preascitic and ascitic cirrhosis. Hepatology 2001 34 : 1113 18.
7. Bernardi M, Trevisani F, De Palma R et al. Chronobiological evaluation of sympathoadrenergic function in cirrhosis. Gastroenterology 1987 93 : 1178 86.
8. Henriksen JH, Ring-Larsen H, Christensen NJ. Sympathetic nervous activity in cirrhosis. A survey of plasma catecholamine studies. J. Hepatol. 1985 1 : 55 65.
9. Henriksen JH, Ring-Larsen H, Christensen NJ. Hepatic intestinal uptake and release of catecholamines in alcoholic cirrhosis. Evidence of enhanced hepatic intestinal sympathetic nervous activity. Gut 1987 28 : 1637 42.
10. Henriksen JH, Moller S, Ring-Larsen H, Christensen NJ. The sympathetic nervous system in liver disease. J. Hepatol. 1998 29 : 328 41.
11. Harbuz M, Rees R, Eckland D, Jessop DS, Brewerton D, Lightman SL. Paradoxical responses of hypothalamic corticotropin-releasing factor (CRF), messenger ribonucleic acid (mRNA) and CRF-41 peptide and adrenohypophysial proopiomelanocortin mRNA during chronic inflammatory stress. Endocrinology 1992 130 : 1394 400.
12. Nakada MT, Stadel JM, Poksay KS, Crooke ST. Glucocorticoid regulation of beta-adrenergic receptors in 3T3-L1 preadipocytes. Mol. Pharmacol. 1987 31 : 377 84.
13. Korn SH, Wouters EF, Wesseling G, Arends JW, Thunnissen FB. Interaction between glucocorticoids and beta2-agonists: alpha and beta glucocorticoid- receptor mRNA expression in human bronchial epithelial cells. Biochem. Pharmacol. 1998 56 : 1561 9.
14. Schmidt P, Holsboer F, Spengler D. Potential glucocorticoid receptor transactivation via G protein betagamma-subunits and the phosphoinositide 3-kinase pathway. Mol. Endocrinol. 2001 15 : 553 64.
15. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes P. Effect of inhaled formoterol and budesonide on exacerbation of asthma. Formoterol and corticosteroids establishing therapy (FACET) International Study Group. N. Engl. J. Med. 1997 337 : 1405 11.
16. Le Roux CW, Chapman GA, Kong WM, Jones J, Alaghband-Zadeh J. Free cortisol index is better than serum total cortisol in determining hypothalamic-pituitary-adrenal status in patients undergoing surgery. J. Clin. Endocrinol. Metab. 2003 88 : 2045 8.
17. Hulting J, Sollevi A, Ullman B, Franco-Cereceda A, Lundberg JM. Plasma Neuropeptide Y on admission to a coronary care unit: raised levels in patients with left heart failure. Cardiovasc. Res. 1990 24 : 102 8.
18. Morris JL, Russell AE, Kapoor V et al. Increases in plasma neuropeptide Y concentrations during sympathetic activation in man. J. Auton. Nerv. Syst. 1986 17 : 143 9.
19. Daughaday WH. Binding of corticosteroids by plasma proteins. III. The binding of corticosteroid and related hormones by human plasma and plasma protein fractions as measured by equilibrium dialysis. J. Clin. Invest. 1958 37 : 511 18.
20. Jessop DS. Stimulatory and inhibitory regulators of the hypothalamo-pituitary-adrenocortical axis. Baillieres Best Pract. Res. Clin. Endocrinol. Metab. 1999 13 : 491 501.
21. Suda T, Tozawa F, Iwai I et al. Neuropeptide Y increases the corticotropin-releasing factor messenger ribonucleic acid level in rat hypothalamus. Brain Res. Mol. Brain Res. 1993 18 : 311 15.
22. Krysiak R, Obuchowicz E, Hermann ZS. Interactions between the neuropeptide Y system and the hypothalamic-pituitary-adrenal axis. Eur. J. Endocrinol. 1999 140 : 130 6.
23. Straub RH, Harle P. Stress, hormones, and neuronal signals in the pathophysiology of rheumatoid arthritis. The negative impact on chronic inflammation Med. Klin. (Munich) 2005 100 : 794 803 (in German).
24. Bichet DG, Van Putten VJ, Schrier RW. Potential role of increased sympathetic activity in impaired sodium and water excretion in cirrhosis. N. Engl. J. Med. 1982 307 : 1552 7.
25. MacGilchrist AJ, Howes LG, Hawksby C, Reid JL. Plasma noradrenaline in cirrhosis: a study of kinetics and temporal relationship to ascites formation. Eur. J. Clin. Invest. 1991 21 : 238 43.
26. Bendtsen F, Henriksen JH, Becker U, Sorensen T. Effect of propranolol on circulating catecholamines in cirrhosis. J. Hepatol. 1990 10 : 198 204.
27. Edvinsson L, Ekman R, Hedner P, Valdemarson S. Congestive heart failure: involvement of perivascular peptides reflecting activity in sympathetic, parasympathetic and afferent fibres. Eur. J. Clin. Invest. 1990 20 : 85 9.
28. Uriz J, Gines P, Ortega R et al. Increased plasma levels of neuropeptide Y in hepatorenal syndrome. J. Hepatol. 2002 36 : 349 55.
29. Pernow J, Lundberg JM, Kaijser L. Vasoconstrictor effects in vivo and plasma disappearance rate of neuropeptide Y in man. Life Sci. 1987 40 : 47 54.
30. Pernow J, Lundberg JM, Kaijser L et al. Plasma neuropeptide Y-like immunoreactivity and catecholamines during various degrees of sympathetic activation in man. Clin. Physiol. 1986 6 : 561 78.
31. Ahlborg G, Lundberg JM. Splanchnic release of neuropeptide Y during prolonged exercise with and without beta-adrenoceptor blockade in healthy man. Clin. Physiol. 1991 11 : 343 51.
32. Rudehill A, Franco-Cereceda A, Hemsen A, Stensdotter M, Pernow B, Lundberg JM. Cigarette smoking-induced elevation of plasma neuropeptide Y levels in man. Clin. Physiol. 1989 9 : 243 8.
33. Lundberg JM, Pernow B, Franco-Cereceda A, Rudehill A. Effects of antihypertensive drugs on sympathetic vascular control in relation to neuropeptide Y. J. Cardiovasc. Pharmacol. 1987 10 (Suppl. 12 51 68.
34. Rosman PM, Farag A, Benn R, Tito J, Mishik A, Wallace E. Modulation of pituitary-adrenocortical function: decreased secretory episodes and blunted circadian rhythmicity in patients with alcoholic liver disease. J. Clin. Endocrinol. Metab. 1982 55 : 709 17.
35. McDonald JA, Handelsman DJ, Dilworth P, Conway AJ, McCaughan GW. Hypothalamic-pituitary adrenal function in end-stage non-alcoholic liver disease. J. Gastroenterol. Hepatol. 1993 8 : 247 53.
36. Fernandez J, Escorsell A, Zabalza M et al. Adrenal insufficiency in patients with cirrhosis and septic shock: effect of treatment with hydrocortisone on survival. Hepatology 2006 44 : 1288 95.
37. Straub RH, Herfarth H, Falk W, Andus T, Scholmerich J. Uncoupling of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis in inflammatory bowel disease? J. Neuroimmunol. 2002 126 : 116 25.
38. Harle P, Straub RH, Wiest R et al. Increase of sympathetic outflow measured by neuropeptide Y and decrease of the hypothalamic-pituitary-adrenal axis tone in patients with systemic lupus erythematosus and rheumatoid arthritis: another example of uncoupling of response systems. Ann. Rheum. Dis. 2006 65 : 51 6.
39. Straub R, Günzler R, Miller LE, Cutolo M, Schoelmerich J, Schill S. Anti-inflammatory cooperativity of corticosteroids and norepinephrine in rheumatoid arthritis synovial tissue in vivo and in vitro. FASEB J. 2002 16 : 993 1000.
40. Kariagina A, Romanenko D, Ren SG, Chesnokova V. Hypothalamic-pituitary cytokine network. Endocrinology 2004 145 : 104 12.
41. Jafarian-Tehrani M, Sternberg EM. Neuroendocrine and other factors in the regulation of inflammation. Animal models. Ann. N. Y. Acad. Sci. 2000 917 : 819 24.
42. Straub RH, Wiest R, Strauch UG, Harle P, Scholmerich J. The role of the sympathetic nervous system in intestinal inflammation. Gut 2006 55 : 1640 9.
43. Straub RH, Harle P. Sympathetic neurotransmitters in joint inflammation. Rheum. Dis. Clin. North Am. 2005 31 : 43 59, viii.
44. McMahon A, Sabban EL. Regulation of expression of dopamine beta-hydroxylase in PC12 cells by glucocorticoids and cyclic AMP analogues. J. Neurochem. 1992 59 : 2040 7.
45. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve - an integrative interface between two supersystems: the brain and the immune system. Pharmacol. Rev. 2000 52 : 595 638.
46. Tilg H, Wilmer A, Vogel W et al. Serum levels of cytokines in chronic liver diseases see comments Gastroenterology 1992 103 : 264 74.
47. Andus T, Gross V, Holstege A, Schölmerich J. Evidence for the production of high amounts of interleukin-6 in the peritoneal cavity. J. Hepatol. 1992 15 : 378 81.
48. Genesca J, Marti R, Rojo F et al. Increased tumour necrosis factor alpha production in mesenteric lymph nodes of cirrhotic patients with ascites. Gut 2003 52 : 1054 9.
49. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005 41 : 422 33.
50. Tazi KA, Quioc JJ, Saada V et al. F-alpha production signaling pathways in monocytes from patients with advanced cirrhosis: possible role of Akt and IRAK-M. J. Hepatol. 2006 45 : 280 9.
51. Harry D, Anand R, Holt S et al. Increased sensitivity to endotoxemia in the bile duct-ligated cirrhotic rat. Hepatology 1999 30 : 1198 205.
52. Felver ME, Mezey E, McGuire M et al. Plasma tumor necrosis factor alpha levels predicts decreased long-term survival in severe alcoholic hepatitis. Alcohol. Clin. Exp. Immunol. 1990 14 : 255 9.
53. Odeh M, Sabo E, Srugo I, Oliven A. Serum levels of tumor necrosis factor-alpha correlate with severity of hepatic encephalopathy due to chronic liver failure. Liver Int. 2004 24 : 110 16.
54. Oppert M, Schindler R, Husung C et al. Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit. Care Med. 2005 33 : 2457 64.
55. Minneci PC, Deans KJ, Banks SM, Eichacker PQ, Natanson C. Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann. Intern. Med. 2004 141 : 47 56.
56. Meggison H, Jones G. Best evidence in critical care medicine: treatment: adrenal replacement therapy improves survival in patients with septic shock. Can. J. Anaesth. 2004 51 : 264 5.
57. Briegel J, Forst H, Haller M et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit. Care Med. 1999 27 : 723 32.
58. Lin RS, Lee FY, Lee SD et al. Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J. Hepatol. 1995 22 : 165 72.